Printer Friendly

TransMedics says trial of Organ Care System successfully perfused heart for transplantation.

TransMedics, Inc., San Francisco, CA, announced results from its European PROTECT 1 clinical trial on its Organ Care System (OCS) in maintaining and transporting donated hearts for transplant surgery had been successful. The company says in the non-randomized, multi-center European study, 20 consented patients received donated hearts that were maintained by the OCS in a perfused, and physiologic beating state for a mean time of 3.7 hours.

TransMedics reports the study met the primary endpoints and achieved a 30-day patient and graft survival of 100%. Additionally, the OCS resulted in rapid time to recovery for patients as evidenced by the median length of time patients spent on a ventilator and in the ICU, which were 10.7 hours and 24.3 hours, respectively. The trial sites participating in the study included the Clinic for Thoracic & Cardiovascular Medicine, Bad Oeynhausen, the Germany Heart Institute in Berlin Germany, the Papworth Hospital in Cambridge, UK and Harefield Hospitals, NHS Trusts in Middlesex, UK.

The company says the patients in the study received hearts within a mean total ischemic time of only 76 minutes. International registry data shows that heart transplant patients who receive a donor heart with 1 hour of ischemic time reduce their risk of dying within a year of transplantation by more than 40% compared to patients who receive a donor organ with 5 hours of ischemic preservation.

TransMedics is presently expanding the number of centers working with the OCS to include hospitals in Italy, Austria and France. Additionally, the company has received FDA approval to initiate clinical trials in the US to evaluate the safety and performance of OCS for heart transplants in the US. The trials will take place in five centers, including the University of Pittsburgh Medical Center, Pittsburgh, PA; UCLA Medical Center in Los Angeles, CA; The Cleveland Clinic Heart and Vascular Institute in Cleveland, OH, The University of Chicago Hospitals and Cardiac Center in Chicago, IL; and Brigham and Women's Hospital in Boston, MA.

Contact: David Kolstad - (978) 552-0927, e-mail: dkolstad@transmedics.com
COPYRIGHT 2007 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Date:May 1, 2007
Words:338
Previous Article:Former Senator Bill Frist, MD, will not be charged with insider trading.
Next Article:Y's Therapeutics initiates Phase II trial with YSPSL to prevent ischemic reperfusion injury in liver transplant patients.
Topics:


Related Articles
Portable perfusion device could increase ischemic time of donor hearts significantly, researchers report.
UMM, Hauser and TransMedics join to develop a new portable organ preservation system.
Human heart kept alive on portable organ preservation system for first time ever at UPMC.
21st century lifeline: redesigning organ transplant transport.
Frustrated by failure to attract new donors, transplant community seems ready to try once taboo methods.
Organ Recovery Systems receives FDA ok to market LifePort Kidney Transporter; Zevex to manufacturer the device.
AST to hold conference on diversity and disparity in transplantation Sept. 21-22 in Washington, DC.
NIAID, NHLBI seeking institutions, individuals to conduct clinical trials in pediatric organ transplantation.
Moment of death: ethical concerns.
Year ends on high note, but 2007 will be remembered for the tragic deaths of U-M transplant recovery team.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters